Use of atorvastatin in systemic lupus erythematosus in children and adolescents

Arthritis and Rheumatism

Volumn 64, Issue 1, 2012, Pages 285-296

  Schanberg, L E ^a   Sandborg, C ^b   Barnhart, H X ^a   Ardoin, S P ^c   Yow, E ^a   Evans, G W ^d   Mieszkalski, K L ^a   Ilowite, N T ^e   Eberhard, A ^f   Imundo, L F ^g   Kimura, Y ^h   Von Scheven, E ⁱ   Silverman, E ^j   Bowyer, S L ^k   Punaro, M ^l   Singer, N G ^m   Sherry, D D ⁿ   McCurdy, D ^o   Klein Gitelman, M ^p   Wallace, C ^q   Silver, R ^r   Wagner Weiner, L ^s   Higgins, G C ^c   Brunner, H I ^t   Jung, L ^u   Soep, J B ^v   Reed, A M ^w   Provenzale, J ^a   Thompson, S D ^t   more..

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONWIDE CHILDREN S HOSPITAL   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f Northwell Health   (United States)

^g Department of Medicine   (United States)

^h HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j HOSPITAL FOR SICK CHILDREN   (Canada)

^k INDIANA UNIVERSITY   (United States)

^l TEXAS SCOTTISH RITE HOSPITAL FOR CHILDREN   (United States)

^m UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

ⁿ CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p NORTHWESTERN UNIVERSITY   (United States)

^q SEATTLE CHILDREN S HOSPITAL   (United States)

^r MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^s UNIVERSITY OF CHICAGO   (United States)

^t CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^u CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^v CHILDREN S HOSPITAL   (United States)

^w MAYO CLINIC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BENIGN TUMOR; BLOOD DISEASE; BODY WEIGHT; CHILD; CHOLESTEROL BLOOD LEVEL; CONGENITAL DISORDER; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CYST; DISEASE ACTIVITY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAMILIAL DISEASE; FEMALE; FOLLOW UP; FRACTIONAL ANISOTROPY; GASTROINTESTINAL DISEASE; GENETIC DISORDER; HEART DISEASE; HEPATOBILIARY DISEASE; HUMAN; IMMUNOPATHOLOGY; KIDNEY DISEASE; LIPID ANALYSIS; LIVER TOXICITY; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; MYALGIA; MYOSITIS; NEUROLOGIC DISEASE; NEUROTOXICITY; NEWBORN DISEASE; NORTH AMERICA; NUTRITIONAL DISORDER; ONSET AGE; PNEUMOCOCCAL INFECTION; POLYP; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PUERPERAL DISORDER; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHABDOMYOLYSIS; SCHOOL CHILD; SEPSIS; SIDE EFFECT; SKIN DISEASE; SOFT TISSUE DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX DISEASE; TREATMENT OUTCOME; ULTRASOUND; UROGENITAL TRACT DISEASE; VASCULAR DISEASE;

ADOLESCENT; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CAROTID INTIMA-MEDIA THICKNESS; CHILD; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HEPTANOIC ACIDS; HUMANS; LIPIDS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PYRROLES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84855264185     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30645     Document Type: Article

References (53)

1. Gladman DD, Urowitz MB,. Morbidity in systemic lupus erythematosus. J Rheumatol SUPPL. 1987; 14 SUPPL. 13: 223-6.
2. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145: 408-15. (Pubitemid 27084212)
3. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-406. (Pubitemid 37542988)
4. Hak AE, Karlson EW, Feskanich D, Stampfer MJ, Costenbader KH,. Systemic lupus erythematosus and the risk of cardiovascular disease: results from the Nurses' Health Study. Arthritis Rheum 2009; 61: 1396-402.
5. Urowitz MB, Gladman D, Ibanez D, Bae SC, Sanchez-Guerrero J, Gordon C, et al, for the Systemic Lupus International Collaborating Clinics. Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010; 62: 881-7.
6. Brunner HI, Gladman DD, Ibanez D, Urowitz MD, Silverman ED,. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum 2008; 58: 556-62. (Pubitemid 351294890)
7. Tucker LB, Uribe AG, Fernandez M, Vila LM, McGwin G, Apte M, et al. Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus 2008; 17: 314-22. (Pubitemid 351655799)
8. Nascif AK, Hilario MO, Terreri MT, Ajzen SA, D'Almeida V, Plavnik FL, et al. Endothelial function analysis and atherosclerotic risk factors in adolescents with systemic lupus erythematosus. Int J Adolesc Med Health 2007; 19: 497-505. (Pubitemid 351278999)
9. Falaschi F, Ravelli A, Martignoni A, Migliavacca D, Sartori M, Pistorio A, et al. Nephrotic-range proteinuria, the major risk factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus. Arthritis Rheum 2000; 43: 1405-9. (Pubitemid 30416328)
10. Schanberg LE, Sandborg C, Barnhart HX, Ardoin SP, Yow E, Evans GW, et al, for the Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators. Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the Atherosclerosis Prevention in Pediatric Lupus Erythematosus cohort. Arthritis Rheum 2009; 60: 1496-507.
11. Soep JB, Mietus-Snyder M, Malloy MJ, Witztum JL, von Scheven E,. Assessment of atherosclerotic risk factors and endothelial function in children and young adults with pediatric-onset systemic lupus erythematosus. Arthritis Rheum 2004; 51: 451-7. (Pubitemid 38725147)
12. Chow PC, Ho MH, Lee TL, Lau YL, Cheung YF,. Relation of arterial stiffness to left ventricular structure and function in adolescents and young adults with pediatric-onset systemic lupus erythematosus. J Rheumatol 2007; 34: 1345-52. (Pubitemid 46898120)
13. Gazarian M, Feldman BM, Benson LN, Gilday DL, Laxer RM, Silverman ED,. Assessment of myocardial perfusion and function in childhood systemic lupus erythematosus. J Pediatr 1998; 132: 109-16. (Pubitemid 28082541)
14. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
15. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009; 338: b2376.
16. Blum A, Shamburek R,. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 2009; 203: 325-30.
17. Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Buller HR, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2004; 292: 331-7. (Pubitemid 38944256)
18. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
19. Bots ML, Evans GW, Riley W, McBride KH, Paskett ED, Helmond FA, et al. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. Eur Heart J 2006; 27: 746-55.
20. Crouse JR III, Grobbee DE, O'Leary DH, Bots ML, Evans GW, Palmer MK, et al. Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin in subclinical atherosclerosis-the rationale and methodology of the METEOR study. Cardiovasc Drugs Ther 2004; 18: 231-8. (Pubitemid 38918958)
21. Kastelein JJ, van Leuven SI, Evans GW, Riley WA, Revkin JH, Shear CL, et al. Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. Curr Med Res Opin 2007; 23: 885-94. (Pubitemid 46631491)
22. Pavlov OV, Bobryshev Y, Balabanov Y, Ashwell K,. An in vitro study of the effects of lovastatin on human fetal brain cells. Neurotoxicol Teratol 1995; 17: 31-9.
23. Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005; 142: 953-62.
24. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363-9. (Pubitemid 26085211)
25. Varni JW, Seid M, Rode CA,. The PedsQL: measurement model for the pediatric quality of life inventory. Med Care 1999; 37: 126-39.
26. National Cancer Institute. Common toxicity criteria version 2.0. URL:.
27. Costenbader KH, Karlson EW, Gall V, de Pablo P, Finckh A, Lynch M, et al. Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus. Arthritis Rheum 2005; 53: 718-23. (Pubitemid 41463837)
28. Bots ML, Evans GW, Riley WA, Grobbee DE,. Carotid intima-media thickness measurements in intervention studies: design options, progression rates, and sample size considerations: a point of view. Stroke 2003; 34: 2985-94. (Pubitemid 37517782)
29. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 1997; 146: 483-94. (Pubitemid 27391409)
30. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE,. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997; 96: 1432-7. (Pubitemid 27375333)
31. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr, for the Cardiovascular Health Study Collaborative Research Group. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340: 14-22. (Pubitemid 29024679)
32. Petri M, Kiani AN, Post W, Magder L,. Lupus Atherosclerosis Prevention Study (LAPS): randomized double blind placebo controlled trial of atorvastatin versus placebo [abstract]. Arthritis Rheum 2006; 54 SUPPL.: S520.
33. Norby GE, Holme I, Fellstrom B, Jardine A, Cole E, Abedini S, et al, on behalf of the Assessment of Lescol in Renal Transplantation Study Group. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study. Arthritis Rheum 2009; 60: 1060-4.
34. De Kruif MD, Limper M, Hansen HR, de Ruiter J, Spek CA, van Gorp EC, et al. Effects of a 3-month course of rosuvastatin in patients with systemic lupus erythematosus. Ann Rheum Dis 2009; 68: 1654.
35. Kotyla PJ,. Comment on: atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 week controlled trial [letter]. Rheumatology (Oxford) 2008; 47: 381-2. (Pubitemid 351267216)
36. Costenbader KH, Liang MH, Chibnik LB, Aizer J, Kwon H, Gall V, et al. A pravastatin dose-escalation study in systemic lupus erythematosus. Rheumatol Int 2007; 27: 1071-7. (Pubitemid 47246586)
37. Espeland MA, O'Leary DH, Terry JG, Morgan T, Evans G, Mudra H,. Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors. Curr Control Trials Cardiovasc Med 2005; 6: 3.
38. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M,. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007; 115: 459-67. (Pubitemid 46184197)
39. Dogan S, Duivenvoorden R, Grobbee DE, Kastelein JJ, Shear CL, Evans GW, et al, on behalf of the RADIANCE 1 and RADIANCE 2 Study Groups. Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia. Ann Med 2010; 42: 447-64.
40. Thompson T, Sutton-Tyrrell K, Wildman RP, Kao A, Fitzgerald SG, Shook B, et al. Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus. Arthritis Rheum 2008; 58: 835-42. (Pubitemid 351364882)
41. Sass C, Herbeth B, Chapet O, Siest G, Visvikis S, Zannad F,. Intima-media thickness and diameter of carotid and femoral arteries in children, adolescents and adults from the Stanislas cohort: effect of age, sex, anthropometry and blood pressure. J Hypertens 1998; 16: 1593-602. (Pubitemid 28515485)
42. Jourdan C, Wuhl E, Litwin M, Fahr K, Trelewicz J, Jobs K, et al. Normative values for intima-media thickness and distensibility of large arteries in healthy adolescents. J Hypertens 2005; 23: 1707-15. (Pubitemid 41233431)
43. Marks D, Thorogood M, Neil HA, Humphries SE,. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003; 168: 1-14. (Pubitemid 36559596)
44. Osterberg L, Blaschke T,. Adherence to medication. N Engl J Med 2005; 353: 487-97. (Pubitemid 41127293)
45. Crouse JR III, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH, et al, for the METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA 2007; 297: 1344-53. (Pubitemid 46513235)
46. Shurraw S, Tonelli M,. Statins for treatment of dyslipidemia in chronic kidney disease. Perit Dial Int 2006; 26: 523-39. (Pubitemid 44669427)
47. Manzi S, Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Rairie JE, Tracy RP, et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 51-60. (Pubitemid 29042570)
48. Maksimowicz-McKinnon K, Magder LS, Petri M,. Predictors of carotid atherosclerosis in systemic lupus erythematosus. J Rheumatol 2006; 33: 2458-63. (Pubitemid 46067826)
49. Roman MJ, Crow MK, Lockshin MD, Devereux RB, Paget SA, Sammaritano L, et al. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2007; 56: 3412-9. (Pubitemid 47585436)
50. Bohm B, Hartmann K, Buck M, Oberhoffer R,. Sex differences of carotid intima-media thickness in healthy children and adolescents. Atherosclerosis 2009; 206: 458-63.
51. Ardoin SP, Schanberg LE,. The management of pediatric systemic lupus erythematosus. Nat Clin Pract Rheumatol 2005; 1: 82-92.
52. Sandborg C, Ardoin SP, Schanberg L,. Therapy insight: cardiovascular disease in pediatric systemic lupus erythematosus. Nat Clin Pract Rheumatol 2008; 4: 258-65. (Pubitemid 351638683)
53. Kavey RE, Daniels SR, Lauer RM, Atkins DL, Hayman LL, Taubert K,. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation 2003; 107: 1562-6. (Pubitemid 36378499)